City of Hope physicians, scientists to address notable advancements in liquid biopsy, genomic profiling at ESMO Congress
September 7, 2017
The European Society for Medical Oncology Congress will hold the 2017 annual meeting on Sept. 8 to 12 in Madrid, Spain.
DUARTE, Calif. — Scientists and researchers at City of Hope, a world-renowned independent research and cancer and diabetes treatment center, will be discussing the advancements in cancer research at the annual European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, on Sept. 8 to 12. City of Hope research will highlight the latest developments in genomic profiling, liquid biopsy, nonsmall lung cancer and metastatic disease, among other advancements.
The ESMO 2017 Congress is the most influential annual meeting of oncology professionals in Europe and brings together more than 22,000 researchers and clinicians from around the world to discuss and better understand the molecular biology underlying the development of cancer.
“The work being done by City of Hope researchers address a variety of challenges in cancer treatment and research,” said Steven T. Rosen
, M.D., provost and chief scientific officer and director of Beckman Research Institute of City of Hope. “The studies being highlighted at ESMO have the potential to improve future approaches in treating cancer and represents City of Hope’s ongoing commitment to developing personalized medicine and targeted therapies for patients.”
The highlighted presentations include:
ABSTRACT 1702O: Clinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNA.
This oral presentation will be presented by Sumanta K. Pal,
M.D., associate clinical professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope on Saturday, Sept. 9, from 16:30 to 18:00. The use of liquid biopsies, a less invasive method of accessing important genomic information in solid tumors, is increasing in clinical care, allowing for more individualized care for advanced-stage cancer patients. Pal and his colleagues have created a dataset of over 30,000 advanced-stage cancer patients, derived from liquid biopsy use in clinical practice, which highlights the clinical impact of identifying alterations that are targetable by drugs with regulatory approval, including emergent resistance alterations.
ABSTRACT 1714P: KRAS in Non-Small Cell Lung Cancer
Lung cancer research done by Ravi Salgia,
M.D, Ph.D., the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and chair of the Department of Medical Oncology & Therapeutics Research, and Idoroenyi Amanan, M.D., a City of Hope fellow, will be presented as part of the poster display session in pathology/molecular biology on Monday, Sept. 11. The team’s work examines disease heterogeneity with variable molecular mutations, which is one of the main contributory factors in nonsmall cell lung cancer. The research found significance of co-mutations and their therapeutic implications, especially in response to immunotherapy agents represents an important step to develop better treatment options for KRAS mutated lung cancers.
ABSTRACT 908P: Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
Results from research led by Cristiane Bergerot, Ph.D., a postdoc fellow at City of Hope, and Pal will be presented as a poster display on Sunday, Sept. 10, from 13:15 to 14:15. Their work investigates data collected from 2001 and 2016 electronic survey, which compromise core items spanning in physician, practical, functional and emotional domains. associating overall survival and depressive symptoms in patients with kidney cancer. Their study suggests a potential link between clinicopathologic criteria and BPSD and recommend targeted interventions to address elements related to BPSD to help improve patient outcomes.
About City of Hope
City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 49 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics
throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report
. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation
and numerous breakthrough cancer drugs
based on technology developed at the institution.
# # #